A Partnership Training Program: Studying Targeted Drug Delivery Using Nanoparticles in Breast Cancer Diagnosis and Therapy
Abstract
In the fourth year of this training grant, 11 faculty, 6 postdocs, 9 graduate and 1 undergraduate students from 7 departments at the Howard University have been trained in using nanoparticles as targeted drug delivery vehicles for cancer diagnosis and therapy. 25 seminars and workshops in cancer, molecular imaging, and nanomedicine have been offered. The trainees have received hands-on training in nanotechnology, MRI and optical imaging, cell biology lab techniques, and small animal handling. We implemented a new NMR method to measure kinetics of chemical exchange of ligand-target complex in solid tumor for pharmacokinetic modeling. We generated a humanized bivalent scFv-derived, DT390-based recombinant immunotoxin, which exhibited high cytotoxicity and anti-tumor efficacy against cancer cells. 16 research projects utilized the Nanomedicine Core. We published 7 research papers and review articles on nanotechnology in cancer research. Nanomedicine Core users have submitted 10 grant applications, and received two new NIH grants. The Core continued to be a synergy center drawing multidisciplinary research using nanotechnology for cancer research.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA613187
Entities
People
- Paul C Wang
Organizations
- Howard University